从大脑到心脏，红杉医疗成员企业收获多项成果｜Healthcare View

Group 1 - The article discusses the first real theater-based neuroaesthetic experiment in China, conducted at Tsinghua University, where eight volunteers wore portable EEG devices while watching a dance performance to capture their neural activity in real-time [3][6]. - The NeuroHUB platform, developed by Boruikang, is highlighted for its ability to achieve millisecond-level synchronization of EEG and physiological signals in a real-world setting, marking a significant advancement in neuroaesthetic research [5][6]. - The experiment demonstrated that audience engagement significantly increases brain activity, revealing the neural connections between emotional responses and artistic experiences [6][7]. Group 2 - NeuroHUB showcases three core advantages: wireless freedom allowing natural seating in the theater, group super-scanning enabling real-time dialogue among multiple brains, and robust interference resistance against complex electromagnetic environments [7][9]. - The platform's modular design and wireless data transmission ensure a seamless experience for participants, maintaining the purity of the artistic experience during the performance [7]. - NeuroHUB's capability to synchronize data from over ten participants simultaneously represents a breakthrough in overcoming the limitations of traditional laboratory settings [8]. Group 3 - The article also mentions advancements in medical technology, including a new integrated solution for coronary function and imaging assessments approved for market release, which combines multiple evaluation metrics for enhanced surgical decision-making [11][12]. - The development of a fully magnetic levitation artificial heart by Xinxin Medical has been recognized as one of the top ten technological advancements in Jiangsu Province, showcasing significant progress in heart failure treatment [13][15]. - The iPSC-derived CAR-NK cell therapy developed by Qihan Biotech has achieved notable clinical results in treating refractory systemic sclerosis, marking a significant milestone in autoimmune disease treatment [16][17]. Group 4 - The article highlights the introduction of two first-in-class drugs by Dige Pharmaceutical, which will be presented at major international conferences, indicating ongoing innovation in the hematology sector [21]. - The J-VALVE TF system's 12-month clinical follow-up results demonstrate superior performance compared to similar products, emphasizing the potential of Chinese-developed medical devices on the international stage [22][24]. - The article concludes with advancements in AI-driven enzyme design and biodegradable medical devices, showcasing the ongoing evolution and innovation within the healthcare and biotechnology industries [25][35].